CADL - Candel Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-2.508M

Cash

51.89M

Avg Qtr Burn

-8.571M

Short % of Float

0.89%

Insider Ownership

33.23%

Institutional Own.

19.18%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CAN-2409 Details Prostate cancer, Cancer, Solid tumor/s	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAN-2409 + Valacyclovir w/ PD-(L)1 targeting agents Details Lung cancer, Cancer, Solid tumor/s, Non-small cell lung carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAN-2409 + Valacyclovir w/ SoC Details Pancreatic cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAN-3110 Details Solid tumor/s, Cancer, Glioma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAN-2409 + Opdivo Details Cancer, Glioma, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.